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Abstract 
 
Background: Recreational use of 3,4 methylenedioxymethamphetamine (Ecstasy, MDMA) is 
increasing worldwide.  Its use by pregnant women causes concern due to potentially harmful 
effects on the developing fetus. MDMA, an indirect monoaminergic agonist and reuptake 
inhibitor, affects the serotonin and dopamine systems. Preclinical studies of fetal exposure 
demonstrate effects on learning, motor behavior, and memory.  In the first human studies, we 
found prenatal MDMA exposure related to poorer motor development in the first year of life.  In 
the present study we assessed the effects of prenatal exposure to MDMA on the trajectory of 
child development through 2 years of age. We hypothesized that exposure would be associated 
with poorer mental and motor outcomes.   
Materials and Methods: The DAISY (Drugs and Infancy Study, 2003-2008) employed a 
prospective longitudinal cohort design to assess recreational drug use during pregnancy and 
child outcomes in the United Kingdom.  Examiners masked to drug exposures followed infants 
from birth to 4, 12, 18, and 24 months of age.  MDMA, cocaine, alcohol, tobacco, cannabis, and 
other drugs were quantified through a standardized clinical interview. The Bayley Scales (III) of 
Mental (MDI) and Motor (PDI) Development and the Behavior Rating Scales (BRS) were 
primary outcome measures.  Statistical analyses included a repeated measures mixed model 
approach controlling for multiple confounders. 
Results:  Participants were pregnant women volunteers, primarily white, of middle class 
socioeconomic status, average IQ, with some college education, in stable partner relationships.   
Of 96 women enrolled, children of 93 had at least one follow-up assessment and 81 (87%) had 
≥ two assessments.  Heavier MDMA exposure, (M = 1.3 ± 1.4 tablets per week) predicted lower 
PDI (p < .002), and poorer BRS motor quality from 4 to 24 months of age, but did not affect 
MDI, orientation, or emotional regulation.  Children with heavier exposure were twice as likely to 
demonstrate poorer motor quality as lighter and non-exposed children (O.R. = 2.2, 95%, CI = 
1.02-4.70, p < .05). 
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Discussion: Infants whose mothers reported heavier MDMA use during pregnancy had motor 
delays from 4 months to two years of age that were not attributable to other drug or lifestyle 
factors.  Women of child bearing age should be cautioned about the use of MDMA and MDMA-
exposed infants should be screened for motor delays and possible intervention. 
 
Keywords:   Behavior, Cocaine, Alcohol, Teratology, 3,4-Methylenedioxymethamphetamine,  
  Infant development, Prenatal, Motor, “Ecstasy”   
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1. Introduction 
Despite its illegal status, 3,4 methylenedioxymethamphetamine (MDMA, “Ecstasy) has 
become a popular recreational drug worldwide over the past two decades, extensively used by 
subgroups of young adults at “rave” dance parties in the U.S., Australia, the United Kingdom, 
and throughout Europe (Parrott AC, 2004).  While primarily taken in pill form, MDMA can also 
be taken as a crystalline powder in drinks, popularized by rock stars as “Molly” in the U.S. and 
“Mandy” in the U.K.  MDMA has also been promoted as a psychotherapeutic agent for the 
treatment of relationship problems and PTSD (Chabrol H, 2013; Greer G & Tolbert R, 1986; 
Sessa B, 2011).  In 2012, the United Nations Office on Drugs and Crime estimated that between 
9.4 and 28.2 million people globally used MDMA at least once (Mohan J ed, June, 2014). In the 
U.S. it is estimated that about 6.2% of individuals 12 years of age or older had used 
Ecstasy.(SAMHSA Center for Behavioral Health Statistics and Quality, 2013) 
MDMA is a ring substituted methamphetamine derivative and a powerful, indirect 
monoaminergic agonist that inhibits the reuptake and promotes the release of serotonin and 
dopamine. It also affects noradrenaline, acetylcholine, and histamine (Green AR, Mechan AO, 
Elliott JM, O'Shea E, & Colado MI, 2003), produces oxytocin release (Kirkpatrick MG, Lee R, 
Wardle MC, Jacob S, & de Wit H, 2014) and reverses the action of the serotonin transporter 
(SERT) leading to depletion of up to 80% of available serotonin with use (Ricaurte GA, Yuan J, 
& McCann UD, 2000). 
Adult use of this central nervous system stimulant with hallucinogenic properties is 
associated with multiple acute and chronic physiological, emotional and cognitive effects. 
Immediate feelings of energy, sociability, euphoria, enhanced sensory perception, and 
emotional connectedness frequently give way to depressive symptoms and executive function 
and memory impairments with chronic use (Parrott AC, 2013).  Current data suggest MDMA is 
more likely to be used by women (Wu LT, Parrott AC, Ringwalt CL, Yang C, & Blazer DG, 
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2009), and is often mistakenly perceived as a safe and even beneficial drug, making it a 
particular concern for women of reproductive age (Sessa B & Nutt D, 2015).   
Several aspects of MDMA use may be particularly harmful during pregnancy and could 
negatively affect fetal outcomes. Maternal appetite suppression, sleep difficulties, increased 
heart rate and body temperature, depressive symptoms, and neurohormonal alterations, 
especially high cortisol levels associated with MDMA use (Parrott AC, Montgomery C et al., 
2014), have all been demonstrated to have detrimental effects on the fetus.  Woman are also 
significantly more at risk of developing hyponatremia following acute MDMA use, especially 
when it is taken at dance clubs or raves (van Dijken GD, Blom RE, Hene RJ, Boer WH, & 
NIGRAM Consortium, 2013).  Moreover, reductions in maternal serotonin levels caused by 
MDMA use may directly adversely affect fetal development as serotonin is involved in control of 
morphogenesis both before and after the appearance of serotonergic neurons (Cote F et al., 
2007). 
MDMA has been demonstrated to cross the placenta in pregnant rats (Campbell NG, 
Koprich JB, Kanaan NM, & Lipton JW, 2006) with correspondent levels in the fetal brain.   
Preclinical studies (Skelton MR, Williams MT, & Vorhees CV, 2008) suggest that fetal exposure 
to MDMA in the third trimester can affect locomotor activity levels and alter risk taking behavior 
and spatial learning (Thompson VB et al., 2009).  Neonatal exposure in rat models, for example, 
produced impaired path integration learning (Vorhees CV, Reed TM, Skelton MR, & Williams 
MT, 2004) possibly through changes in the release of dopamine and serotonin in the striatum 
and hippocampus (Galineau L et al., 2005).  MDMA treatment prenatally of pregnant rats led to 
reduced bodyweight and reduced learning of motor skills in adulthood (Adori C et al., 2010), and 
growth retardation and poorer motor skills in BALB/C mice pups.  MDMA exposure in 6 day old 
rat pups also facilitated neuronal death in cortical, thalamic, and hypothalamic brain regions 
(Dzietko M et al., 2010), as had been shown previously by Meyer (Meyer JS, Grande M, 
Johnson K, & Ali SF, 2004). 
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Pregnancy outcomes after MDMA use have been examined in only a few studies. In a 
retrospective study in the U.K., prenatal MDMA exposure was associated with an increase in 
congenital defects and cardiovascular anomalies (McElhatton PR, Bateman DN, Evans C, 
Pughe KR, & Thomas SH, 1999).  Similar cardiac malformations as well as spontaneous 
abortions were noted in another study in the Netherlands (van Tonningen-van Driel MM, Garbis-
Berkvens JM, & Reuvers-Lodewijks WE, 1999).  Our small prospective, controlled study of 
pregnant women who used MDMA primarily in the first and second trimesters found no effects 
on fetal growth outcomes, but there were differences in sex ratio, with more males in the MDMA 
group. One infant in the MDMA-exposed group was born with Townes-Brocks Syndrome 
(Singer LT et al., 2012a).  When the same cohort was followed over the first year of life, motor 
delays were seen at four months and persisted to 12 months of age. MDMA-exposed infants 
were delayed in standing and walking progressions as well as in mental development, with a 
dose-response relationship of heavier exposure predicting greater delay, after control for 
confounding variables (Singer LT et al., 2012b).  At 24 months, the heavier group also had 
motor deficits compared to light and non-exposed children (Singer LT et al., 2015). 
Little is known about patterns of use, and the demographics of women who use MDMA 
during pregnancy.  Ho et al, 2001 (Ho E, Karimi-Tabesh L, & Koren G, 2001) reported on a 
prospective observational study of 132 pregnant MDMA using women who contacted a risk 
assessment program and were compared to callers who did not use MDMA. MDMA users 
reported greater use of tobacco, alcohol, cocaine, and other illicit drugs than non-users and 
were more likely to be unmarried with psychiatric problems. However, in our U.K. study of 
pregnancy and infant outcomes reported above, MDMA users were not different from non-users 
in sociodemographic characteristics but they were similar to Ho’s study in that they were higher 
users of alcohol and several other illicit drugs (Moore DG et al., 2010). 
The present study extends our prior findings by follow-up of this U.K. cohort beyond 12 
months to two years of age and by using longitudinal analyses to assess the effects of MDMA 
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over time, while also assessing the effects of other drugs, maternal psychological distress, 
gender, and the quality of the home environment on the trajectory of mental and motor 
developmental outcomes. 
2. Methods 
2.1 Participants 
 
Methods and Procedures from this study have been reported previously (Moore DG et 
al., 2010; Moore DG et al., 2011; Singer LT et al., 2012a; Singer LT et al., 2012b; Singer LT et 
al., 2015), but will be reviewed here.  Prospective recruitment of all mothers and infants was 
conducted through the Case Western Reserve University (CWRU) and University of East 
London (UEL) Drugs and Infancy Study (DAISY) that focused on recreational drug use in 
pregnant women (Moore DG et al., 2010; Moore DG et al., 2011).  Recruitment was 
implemented through either referral by midwives, response to leaflets describing the study 
distributed at prenatal clinics, or advertisements in pregnancy magazines. Study description 
requested participation of pregnant women who had used recreational drugs during pregnancy 
such as ecstasy, tobacco, cannabis, alcohol, and cocaine were asked to participate.  
Exclusionary factors included maternal/child HIV positive status, maternal moderate/severe 
intellectual disability or severe psychiatric or medical illness; or, for the child, other major 
medical illnesses. All participants were informed that their data would remain confidential and 
gave informed written consent under protocols approved by university (CWRU and UEL) and 
National Health Service (UK) ethics committees. 
Of 126 women initially recruited, five did not meet study criteria, and 25 did not come to 
the first visit of 96 subjects enrolled and seen for infant 82 (85%) infants were seen at one 
month, 87 (91%) at four months, 79 (82%) at 12 months, 67 (70%) at 18, and 66 (69%) at 24 
months.  Over the two year period, 93 children (25 MDMA (12 lighter, 13 heavier), 68 non-
MDMA) had at least one Bayley assessment with 87% (n = 81) ≥ two assessments. The three 
mothers whose babies were not assessed were lighter MDMA users. Attrition did differ by group 
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(whether MDMA was defined as yes vs no, or none, light, or heavy). Those lost to follow-up at 
24 month assessments were more likely to have lower family income and lower WASI Block 
Design and Similarities scores.  They did not differ in maternal age, race/ethnicity, education, 
parity, psychological distress (GSI), DAST scores, amount of substances used during 
pregnancy, infant birth outcomes (gestational age, weight, length, head circumference), or 
gender. 
2.2 Measures of MDMA Exposure and Covariates 
Maternal interviews were conducted by trained research assistants either in parents’ 
homes, at the UEL laboratory, or by telephone. Interviews occurred over the course of their 
pregnancy on three separate occasions, but if needed, a combined set of interviews was given 
on one occasion if enrollment was late in the pregnancy (Moore DG et al., 2010).  Sixty two 
women completed the interview during pregnancy, with 24 interviewed postnatally.   
2.3 Prenatal Levels of Drug Exposure 
The interview was an adaptation of the Maternal Post-Partum Interview used in prior 
U.S. studies of alcohol and cocaine exposure (Singer LT et al., 2002). Women were requested 
to describe their intake of substances commonly used in UK cohorts based on prior UEL drug 
questionnaires (Parrott AC, Milani RM, Parmar R, & Turner JD, 2001).  Part 1 requested 
information about total lifetime drug use and use during the year leading up to conception. Part 
2 asked about drug use in the month prior to pregnancy and over the first two trimesters, and 
Part 3 asked about use in the last trimester. For each section, values were computed for 
tobacco/cigarettes (#), alcohol (# units) (10 ml in the U.K.), marijuana joints/cigarettes (#), 
MDMA tablets (#), heroin, cigarettes or injections (#), ketamine (grams), crack (# rocks) or 
cocaine (# lines), benzodiazepine and LSD tablets (#), and hallucinogenic mushrooms (#).  
Frequency of use for each drug was recorded on a scale ranging from zero (none) to seven 
(daily use). An average dose per week for each drug was calculated by multiplying the 
frequency by the amount taken per occasion. Users were women that self-admitted to MDMA 
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use at any time during pregnancy or in the month prior to pregnancy. Women who had used 
prior to this time point but reported no use during pregnancy (n = 32) or who had never used 
were classified as non-users, since we were interested in the outcome of fetal exposure.  
Users were divided into heavier (n = 13) and lighter (n = 15) groups based on a median 
split for the amount of MDMA taken averaged over the pregnancy (median = 0.14). Heavier 
users averaged 3.3 (? 4) tablets in the month prior to pregnancy compared to .12 ? .2 tablets for 
lighter users (Wilcoxin test p < .007); 1.6 ? 2 vs. .12 ? 1 tablets in the first trimester (p < .12), 
and .15 ? .6 vs. .02 ? .1 in the second trimester, p > .20.  Since only one mother reported using 
MDMA in the third trimester, we also calculated means excluding the third trimester for heavier 
and lighter users to reflect actual exposure.  Excluding the third trimester, heavier users 
averaged 1.7 ± 1.8 tablets per week (R = .22-6.0) and lighter users averaged .09 ± .06 tablets 
per week (R = .02-.19). 
The initial interview also obtained information for each drug on age at first use, age when 
drug use was discontinued, and typical and highest consumption (Singer LT et al., 2012a).   
2.4 Maternal Drug Use, Demographics, and Psychological Measures 
The Drug Abuse Screening Test (DAST) (Skinner HA, 1982) was given at first interview 
to characterize level of drug dependence. The DAST yields a quantitative index of the degree of 
problems related to drug use, with a cutoff score of 16 (out of 20) indicating a severe level of 
secondary problems in life areas of marital and social relations, and employment, legal, 
physical, and medical problems. 
At each visit, the Brief Symptom Inventory (BSI) (Derogatis LR, 1992), a widely used 
self-report, 53 item questionnaire was also given to describe experience of a range of 
psychiatric symptom patterns. The BSI yields 9 subscales (somatic complaints, obsessive 
compulsive behavior, interpersonal sensitivity, depression, anxiety, phobic anxiety, paranoid 
ideation, hostility and psychoticism) that possess consensually valid clinical significance. A 
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summary score, the General Severity Index (GSI), measures overall psychological distress. Cut 
off scores identify subjects whose symptoms reach severity levels suggestive of the need for 
clinical intervention, i.e. > the 84th percentile (moderate) or > the 98th percentile (severe) 
compared to same sex, non-patient norms. BSI data from the one month visit were used 
because initial differences between MDMA and non-MDMA groups declined over time (Turner 
JJ et al., 2014). 
Data on maternal age at infant birth, marital status, ethnicity, educational level, and 
household income were obtained. After infant birth, fetal growth measurements (weight, length, 
head circumference, and gestational age) and health information were taken from hospital 
records. Women were also administered two subsets of the Wechsler Abbreviated Scale of 
Intelligence (WASI) (Wechsler D, 1999), a standardized IQ test, i.e. the Block Design, and the 
Similarities Scales. Each scale yields a t score with a mean of 50 and a standard deviation of 8. 
At each visit, the Home Observational Measure of the Environment (HOME was administered in 
interview format to measure the quality of the caregiving environment (Caldwell Bettye M & 
Bradley Robert H, 1984). 
2.5 Infant Developmental Outcomes 
The Bayley Scales of Infant Development III (Bayley N, 1993) are standardized 
assessments of infant development that were administered at four, 12, 18, and 24 months of 
age. The Mental Scale yields a Mental Development Index (MDI), a standard score reflecting 
memory, language, and problem solving abilities. The Psychomotor Index (PDI) measures gross 
and fine motor control and coordination. Normative data from the scales yield a mean of 100 
and standard deviation of 15. The Behavioral Rating Scale (BRS) assesses quality of infant 
performance across several developmental domains based on the assessor’s observations. 
Domains include orientation/engagement, emotional regulation, and motor quality at all ages, 
and attention/arousal, which is measured at 4 months of age only.  Motor quality considers the 
overall quality of muscle tone and fine and gross motor movements. Percentile scores are 
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derived from the total raw and factor scores. BRS scores can be categorized as within normal 
limits, questionable, and non-optimal. All assessors were master's level psychology assistants 
or the equivalent who were masked to infant drug exposure. 
3. Statistical Analyses  
Descriptive statistics were used to compare sample characteristics of three MDMA 
groups. The effects of MDMA (heavy, light, none) on MDI, PDI, and two subscales of the BRS 
(emotional regulation and orientation) were evaluated using a repeated measures mixed model 
approach with a random intercept. An unstructured covariance matrix was used to account for 
correlated responses within a subject. Percentile scores for the BRS motor quality subscale 
were dichotomized at ≥ 75% due to its skewed distribution, which was tested using repeated 
measure mixed logistic models also with a random intercept and an unstructured covariance 
matrix. The actual age of the child was used instead of assessment wave to better capture 
variability and trends over time. Due to a possible curvilinear relationship between outcomes 
and test age, a quadratic term  [age (2)] was evaluated. We tested the homogeneity of MDMA 
effects, as well as the effects of gender and other covariates on infant development over time by 
including an interaction term with test age. If the interaction was significant at p < .10, the 
interaction terms were included in the model. Missing data were modeled using full-information 
maximum likelihood, which utilizes all available information from the observed data.  Since the 
Attention/Arousal factor was assessed only at 4 months, multiple linear regression was used for 
that variable.  
Covariates that differed by MDMA status at p <.2 and were associated with the given 
outcome  at p < .2 for at least two time points were evaluated in the multivariable model 
stepwise and retained if, on entry, they were significant at p < .10 or caused substantial change 
(> 10%) in the MDMA coefficient. Adjusted least squares mean (Madj) and standard errors (SE) 
were calculated from the models. MDMA status by gender interactions were also evaluated. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
12 
 
4. Results 
4.1 Maternal Demographics and Drug use 
Table 1 reports demographic, medical, and psychological characteristics of women who 
used MDMA (heavier and lighter groups) vs. women who did not use MDMA while pregnant and 
their pregnancy outcomes. As reported previously (Singer LT et al., 2012a; Singer LT et al., 
2012b) the maternal sample was primarily white; married or with a partner; with some university 
education; came from a full range of socioeconomic (SES) classes, with many from middle and 
high SES backgrounds; and were overall in the average range of intellectual ability. MDMA 
using women  had fewer children.  Overall prenatal drug use and the negative sequelae of drug 
use as measured by the DAST were different among the groups (Table 1). Women who used 
MDMA during pregnancy had higher scores on the DAST, indicating greater severity of 
sequelae related to their drug use. However, the mean scores were below clinical significance 
for both groups, with <5% for each group scoring above the cutoff of 16. All births were 
singleton births. Child birth outcomes (Table 1) did not differ by group in gestation period, 
birthweight, prematurity, length, or head circumference although this finding is inconclusive for 
birth length and head circumference due to missing data.  As reported previously (Singer LT et 
al., 2012a), however, MDMA-exposed infants were significantly more likely to be male (71% vs. 
46%). This remained the case even after controlling for other drug use differences with the O.R. 
of having a male birth after MDMA exposure = 3.2, (95% CI: 1.2-8.2, p < .02).  
Because one child in the MDMA-exposed group was diagnosed with Townes-Brocks 
Syndrome, a rare genetic autosomal dominant multiple malformation of the gene SALL1 (Powell 
CM & Michaelis RC, 1999), all outcome analyses with significant findings were rerun excluding 
this child and results did not differ. Thus, the presented findings include all in the MDMA-
exposed group (Singer LT et al., 2012a). 
Table 2 describes the group average and median drug use during pregnancy for the 
three groups across the full range of substances reported. MDMA users were more likely to use 
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marijuana, cocaine, LSD, and mushrooms during their pregnancy. There were few overall 
differences.   
4.2 Models 
We tested the main effects of and the interactions of level of MDMA prenatal exposure 
and infant test age on BSID III measures over time (Table 3). There was a significant effect of 
level of MDMA exposure on PDI over time (F = 6.90, p < .002), adjusted for child gender, test 
age, test age (2) , gender x child test age, parity and amount of prenatal cocaine exposure.  
Children with heavier exposure had on average an 11-point deficit in PDI compared with lighter 
exposed children and a 6-point deficit compared to non-exposed children over the first two 
years of life (Figure 1).  There was no effect of MDMA exposure on the MDI (F = 1.28, p < .29) 
adjusted for child test age, the HOME score at 12 months, child gender, and gender x child test 
age.   There were significant effects of exposure on BRS motor quality, adjusted for test age, 
child gender, and the HOME score. Children with heavier MDMA exposure were twice as likely 
to be rated by examiners as demonstrating poorer motor quality (OR=2.19, 95%CI= 1.02-4.70, p 
< .045) than lighter and non-exposed children.  
The Attention/Arousal subdomain of the BRS was measured only at 4 months.  Heavier 
MDMA-exposed infants were perceived as having poorer attentional skills than lighter exposed 
infants (p < .001) and there was a non-significant trend for them to perform more poorly than 
non-exposed infants (p < .10) (See Table 3).  There were no reliable effects on BRS orientation 
or emotional regulation.  No test age by MDMA interaction was found, indicating that the effects 
of MDMA on the outcomes did not significantly vary over the first two years of life.  
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
14 
 
 
 
Figure 1.  Estimated Means of Bayley Psychomotor Development Index by level of MDMA 
exposure at each assessment age, adjusted for age2, infant gender, interaction of  infant gender 
and assessment age, parity, and prenatal cocaine exposure.  Heavier group differs from None 
(p < .05) and from Lighter group (p <.001).  
 
Covariate Effects 
Covariate effects were found for the HOME measure and gender.  Although boys had higher 
scores on the MDI and PDI than girls at baseline assessment (Table 3), there were significant 
gender by age interactions that resulted in boys performing worse than girls as they got older.  
The mean MDI at 24 months was 95.58 (SE = 1.81) for boys vs. 106.44 (SE = 1.90) for girls, 
while PDI at 24 months was 93.24 (SE = 1.65) for boys vs. 101.81 (SE = 1.92) for girls.  Higher 
quality of the home environment was also a predictor of a higher MDI score and better 
emotional regulation and motor quality over time as rated by examiners.  Adverse effects of 
prenatal alcohol exposure on motor development, seen at 4 months, were not a significant 
factor on the overall trajectory of the PDI. 
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5. Discussion 
In this longitudinal study, infants whose mothers self-reported heavier MDMA use in the 
month prior to and during pregnancy had persistent motor delays from 4 months to two years of 
age. The effects of MDMA could not be attributed to other drug or alcohol exposures nor to 
sociodemographic factors. Motor skill deficits/delays had been apparent as early as four months 
of age (Singer LT et al., 2012a) and also at 12 months, when the heavier MDMA-exposed 
cohort exhibited deficits in standing and walking progressions compared to non-exposed infants 
(Singer LT et al., 2012b),  Thus, the current study indicates a pervasive and continuing deficit in 
motor skills over the first 2 years of life compared to lighter and non-exposed children. 
There were no effects on MDI.  Prior effects of MDMA on MDI seen at 12 months were no 
longer significant once the overall trajectory of development was considered. 
MDMA affects the serotonin (5-HT) neurotransmitter that plays a key role in regulating brain 
development (Bonnin A & Levitt P, 2011). MDMA also increases cortisol levels in adult users, 
which may have indirect effects on fetal serotonergic activity (Parrott AC, Moore DG et al., 
2014).  There are no other human studies of the developmental outcomes of infants exposed to 
MDMA for comparison. 
Our findings are consistent with a number of preclinical studies.  Increases in dopaminergic 
fibers in areas critical to attention, reward, and motor behavior have been noted (Thompson VB 
et al., 2012) after MDMA exposure.  Adori et al (Adori C et al., 2010) found that intermittent 
MDMA exposure with a low cumulative dose early in gestation such as in this sample was 
related to reduced muscle strength and reduced motor skill learning of offspring in adulthood.  
Similarly, decreased motor function in exposed mouse pups has been noted by Kaizaki (Kaizaki 
A, Tanaka S, Yoshida T, & Numazawa S, 2014). 
Although there are no comparable human studies of MDMA exposure, after prenatal 
exposure to methamphetamine, a similar amphetamine type drug, Smith et al (Smith LM et al., 
2015) found that methamphetamine-exposed infants demonstrated motor deficits relative to 
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comparison infants.  Specifically, they identified poorer quality of movement in the neonatal 
period, and decreased grasping skill with heavier exposure at 1 and 3 years (Smith LM et al., 
2015).   
There are a number of potential mechanisms for MDMA effects on motor development.  The 
neurotransmitter serotonin is a particular target of MDMA and maternal depletion of serotonin 
during pregnancy may have adverse effects on the development of the fetal brain, particularly in 
motor development (Jacobs BL & Fornal CA, 1995; Wurtman RJ, 2005) 
Although the sample size of the present study is small, the homogeneity of the sample, 
primarily middle-class, employed, married, and without significant social problems associated 
with drug use, enhances confidence in the findings, as does the study’s prospective, longitudinal 
design, the measurement and control of a large number of confounding variables, and the 
voluntary recruitment of the sample. The small sample size of heavier users precluded 
evaluating drug interaction effects, which may be important, as simultaneous use of MDMA and 
alcohol is prevalent, as in this sample, and has been demonstrated to have gender specific 
effects on exploratory behavior and working memory in preclinical studies (Canales JJ & Ferrer-
Donato A, 2014).  Additional limitations include the lack of confirming biomarkers, absence of 
data on paternal drug use and possible sampling bias associated with volunteers. 
6. Conclusion 
Despite these limitations, the deficits in motor skills identified early in infancy and persisting 
until two years of age associated with heavier MDMA prenatal exposure are of significant 
concern. Most women in this study discontinued MDMA use after the first trimester, indicating 
that alterations occurred early in fetal development. Discontinuance of use after the first 
trimester (Moore DG et al., 2010), also suggests unplanned pregnancy. MDMA use has been 
associated with raised libido and sexual risk-taking at higher doses, including unprotected sex 
(McElrath K, 2005; Topp L, Hando J, & Dillon P, 1999).  Given the extensive global recreational 
use of MDMA, women of child bearing age should be cautioned about possible harm to the 
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fetus. Further studies are needed to confirm these findings as well as to determine if there are 
long-term effects of exposure.  
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Table 1: Sample Characteristics at Birth by Heavier, Lighter, and Non-MDMA Exposure 
(N=93) 
 MDMA Status  
 Heavier  
(n=13) 
Lighter 
 (n=12) 
None  
(n=68) 
p 
Maternal Characteristics     
White, n (%)  12 (92) 10 (83) 51 (75) .35 
Registered Disabled, n (%) 0 0 5 (8)  .40 
Married/with partner, n (%) 10 (77) 9 (75) 57 (84) .68 
Family Income, n (%)    .51 
   <10K British Pounds 0 4 (33) 13 (19)  
   10-40K British Pounds 9 (69) 6 (50) 40 (59)  
   >40K British Pounds 4 (31) 2 (17) 15 (22)  
Maternal age at birth, M (SD) 26·8 (6.9) 29·5 (5.3) 30·3 (6.4) .21 
Maternal education, M (SD) 15.0 (2.5) 15.5 (3.2) 14.9 (2.9) .84 
WASI Block Design, M (SD)d 55.6 (9.48) 60.0 (5.32) 56.0 (9.5) .50 
WASI Similarities, M (SD) 48.1 (8.0) 56.3 (7.8) 49.4 (8.9) .09 
Parity, M (SD) 1.15 (.37) 1.25 (.45) 1.88 (1.11) .01a 
GSI at birth, M (SD)e .72 (.89) .86 (.82) .54 (.56) .31 
DAST score, M (SD)f 7.4 (4.3) 7.8 (3.5) 4.6 (4.4) .02b 
HOME score at 12 month, M (SD)g 40.4 (3.36) 39.9 (3.09) 39.6 (3.42) .73 
Child Characteristics     
White, n (%) 10 (77) 9 (75) 51 (75) .99 
Male, n (%) 8 (62) 10 (83) 31 (46) .04c 
Special Baby Care Unit, n (%) 1 (8) 1 (8) 8 (12) .86 
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Gestation, weeks, M (SD) 40.1 (1.21) 40.1 (2.11) 39.5 (1.5) .30 
Preterm (< 37 Weeks), n (%) 0 1 (8.3) 1 (1.5) .27 
Birth Weight (g), M (SD) 3537 (522) 3513 (553) 3344 (511) .34 
Birth Length (cm), M (SD) 52.9 (1.55) 50.6 (2.88) 51.4 (2.70) .44 
Head Circumference (cm), M (SD) 34.1 (1.90) 35.7 (1.83) 34.3 (1.90) .20 
a Significant post-hoc (p <.05) difference with Tukey correction between Heavier group vs. None 
b No significant post-hoc group difference 
c Significant difference between MDMA exposed group vs. None 
d Wechsler Abbreviated Scale of Intelligence 
e General Severity Index 
f Drug Abuse Screening Test 
g Home Observational Measure of the Environment   
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Table 2: Maternal Drug Use During Pregnancy by Heavier, Lighter, and Non-MDMA Exposurea 
 MDMA Status  
 Heavier (n=13) Lighter (n=15) None (n=68)  
Drug, per week Mean (SD) Median 
(Range) 
Mean (SD) Median 
(Range) 
Mean (SD) Median 
(Range) 
p 
Cigarettes 50.2 (39.9) 45.0 (0-118) 23.8 (36.8) 9.6 (0-123) 32.5 (49.1) 13.19 (0-280) .10 
Alcohol, units 12.5 (16.0) 4.9 (.06-51) 6.06 (4.52) 5.25 (0-14.7) 6.6 (12.9) 2.3 (0-84) .12 
Marijuana, joints 9.9 (24.2) .25 (0-87.5) 9.51 (14.79) 3.40 (.01-3.4) 6.3 (15.0) 0.06 (0-88) .04 
MDMA, tablets 1.3 (1.4) .75 (.17-4.5) .07 (.04) .06 (.01-.14) -- -- -- 
Cocaine, doses .15 (.28) .05 (0-1.0) .24 (.64) .005 (0-2.4) .02 (0.1) 0 (0-.8) .0001b 
Crack, rocks .04 (.11) 0 (0 - .37) .01 (.04) 0 (0 - .17) 1.0 (5.0) 0 (0-38) .81 
Amphetamine, doses .03 (.10) 0 (0 - .33) .05 (.14) 0 (0 - .52) .0003 (.001) 0 (0-.01) .09 
Mushrooms, doses .02 (.07) 0 (0 - .25) .003 (.007) 0 (0 - .02) 0 (0) 0(0-0) .02 
Tranquilizers, doses .23 (.83) 0 (0 - 3) .003 (.01)  0 (0 - .04 .4 (1.9) 0 (0-11) .87 
Opiates, doses .25 (.86) 0 (0 - 3.13) .02 (.08) 0 (0-.31) .2 (1.2) 0 (0-8) .71 
LSD, doses 0 0 .03 (.07) 0 (0 - .25) 0 (0) 0(0-0) .0003 
Ketamine .13 (.49) 0 (0 - 1.75) .001 (.005) 0 (0 - .02) 0 0 .08 
a Kruskal-Wallis test 
b post-hoc test Lighter group differ from None (p<.02)  
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Table 3. Adjusted Effects of Level of MDMA on Bayley Scales of Infant Development and Behavioral Rating Scales from 4-24 
Months 
 Bayley Scales of 
Mental 
Development 
(MDI) 
Bayley Scales of 
Motor 
Development 
(PDI) 
 
Attention/Arousal 
(at 4 months) 
Orientation/ 
engagement 
Emotional 
regulation 
Motor quality  
(≥ 75%) 
Estimate 
(se) 
p Estimate 
(se) 
p b (se) p Estimate 
(se) 
p Estimate 
(se) 
p Estimate 
(se) 
p 
Non MDMAa 2.78 
(1.80) 
.14 6.16 
(2.56) 
.02 12.64 
(7.60) 
.10 1.24 
(7.02) 
.86 -1.85 
(7.48) 
.81 0.75 
(0.40) 
.06 
Lighter MDMAa 3.26 
(2.31) 
.16 11.46 
(3.09) 
<.001 21.48 
(10.00) 
.03 10.83 
(8.84) 
.23 0.42 
(9.44) 
.96 0.93 
(0.41) 
.02 
Age 0.45 
(0.12) 
<.001 -0.71 
(0.48) 
.14 -1.30 
(2.34) 
.58 -8.64 
(2.85) 
.003 -5.08 
(2.83)  
.08 0.08 
(0.02) 
<.001 
Age2   0.04 
(0.02) 
.01 ---  0.23 
(0.08) 
.003 0.15 
(0.07) 
.04   
Male 5.31 
(2.19) 
.02 7.98 
(2.77) 
.005 8.79 
(5.13) 
.09 -14.61 
(4.88) 
.004 -15.31 
(5.16) 
.004 -0.52 
(0.28) 
.06 
Male*Age -0.72 
(0.17) 
<.001 -0.69 
(0.16) 
<.001 ---        
Alcohol        3.74 
(2.21) 
.096     
Cocaine    -9.55 
(7.21) 
.19         
HOME Score  0.69 
(0.18) 
<.001   ---  0.75 
(0.70) 
.29 1.45 
(0.72) 
.046 0.06 
(0.03) 
.053 
Parity    -0.85 
(0.77) 
.27         
Note. Blank space indicates that the variable did not meet the criteria (e.g., not significant at the bivariate level) and therefore not included in the 
model; --- indicates variables not applicable.  a The reference group is Heavier MDMA group. Males are coded as 1, females 0. 
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Highlights 
? Recreational use of 3,4 methylenedioxymethamphetamine (Ecstasy, MDMA) is 
increasing worldwide. 
? Reductions in maternal serotonin levels caused by MDMA use may adversely affect fetal 
development. 
? In this longitudinal study, higher levels of maternal MDMA use prenatally predicted 
poorer motor development from 4-24 months of age. 
? Women of childbearing age should be cautioned about use of MDMA during pregnancy. 
